ES2847288T3 - Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado - Google Patents

Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado Download PDF

Info

Publication number
ES2847288T3
ES2847288T3 ES09704030T ES09704030T ES2847288T3 ES 2847288 T3 ES2847288 T3 ES 2847288T3 ES 09704030 T ES09704030 T ES 09704030T ES 09704030 T ES09704030 T ES 09704030T ES 2847288 T3 ES2847288 T3 ES 2847288T3
Authority
ES
Spain
Prior art keywords
liver
pres
hbv
compound
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09704030T
Other languages
English (en)
Spanish (es)
Inventor
Walter Mier
Uwe Haberkorn
Stephan Urban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Heidelberg
Original Assignee
Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Heidelberg filed Critical Universitaet Heidelberg
Application granted granted Critical
Publication of ES2847288T3 publication Critical patent/ES2847288T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6036—DNA rev transcr viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09704030T 2008-01-25 2009-01-26 Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado Active ES2847288T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6234708P 2008-01-25 2008-01-25
PCT/EP2009/000477 WO2009092612A1 (en) 2008-01-25 2009-01-26 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver

Publications (1)

Publication Number Publication Date
ES2847288T3 true ES2847288T3 (es) 2021-08-02

Family

ID=40521848

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09704030T Active ES2847288T3 (es) 2008-01-25 2009-01-26 Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado

Country Status (6)

Country Link
US (1) US9868768B2 (enExample)
EP (1) EP2245047B1 (enExample)
JP (1) JP5686468B2 (enExample)
CN (1) CN102015753A (enExample)
ES (1) ES2847288T3 (enExample)
WO (1) WO2009092612A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281761A1 (en) 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
US9381226B2 (en) 2007-02-08 2016-07-05 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US8875361B2 (en) 2008-05-21 2014-11-04 Wirtz Manufacturing Co., Inc. Reformed battery grids
US9393299B2 (en) * 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
WO2012106403A2 (en) * 2011-02-01 2012-08-09 Uab Research Foundation Methods and compositions for pseudoinfectious alphaviruses
CN103402546B (zh) * 2011-02-10 2018-04-13 海德堡鲁普雷希特卡尔斯大学 用于肝特异性诊断的疏水性修饰肽
BR112013020368B1 (pt) * 2011-02-10 2022-08-02 Ruprecht-Karls-Universitãt Heidelberg Peptídeos modificados hidrofóbicos e uso dos mesmos para alvo específico no fígado
JP6205345B2 (ja) * 2011-03-28 2017-09-27 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション ウイルス侵入の阻害に関する方法および組成物
WO2013159243A1 (en) * 2012-04-25 2013-10-31 National Institute Of Biological Sciences, Beijing Compositions and uses of functional receptor for hbv/hdv virus
EP2703001A1 (en) 2012-08-26 2014-03-05 XAX Kft. Tumor vaccination
CN103665095A (zh) * 2012-09-11 2014-03-26 中国人民解放军军事医学科学院卫生学环境医学研究所 一种疏水性多肽修饰抗体的合成方法
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
WO2014072524A1 (en) 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
KR20230156963A (ko) * 2014-10-07 2023-11-15 엠와이알 게엠베하 Hbv 및 hdv 감염의 조합 치료법
EP3138579A1 (en) * 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
EP3189850A1 (en) * 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv
CN109069577B (zh) 2016-01-07 2022-08-19 纳维根公司 Hiv进入的d-肽抑制剂以及使用方法
WO2018054891A1 (en) 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections
EP3392267A1 (en) * 2017-04-18 2018-10-24 Myr GmbH Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
CN109718364A (zh) * 2017-10-27 2019-05-07 上海贺普药业股份有限公司 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
EP3804750A1 (en) 2019-10-10 2021-04-14 Universität Heidelberg Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases and for targeting ntcp
CA3169031A1 (en) * 2020-02-27 2021-09-02 Trushar R. PATEL Polypeptides directed against viral infection and uses thereof
KR20240052981A (ko) 2021-09-14 2024-04-23 어드바팜 게엠베하 신규 지질펩티드 제형
WO2025031397A1 (zh) * 2023-08-08 2025-02-13 前沿生物药业(南京)股份有限公司 钠离子-牛磺胆酸共转运蛋白长效抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
EP1281761A1 (en) * 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
CN101045156B (zh) * 2006-03-29 2012-05-02 刘宏利 特异靶向性药物及其用途
US8748373B2 (en) * 2007-02-21 2014-06-10 Fox Chase Cancer Center Hepatitis B virus compositions and methods of use

Also Published As

Publication number Publication date
EP2245047B1 (en) 2020-11-18
WO2009092612A1 (en) 2009-07-30
CN102015753A (zh) 2011-04-13
US9868768B2 (en) 2018-01-16
US20110027183A1 (en) 2011-02-03
JP2011512123A (ja) 2011-04-21
JP5686468B2 (ja) 2015-03-18
EP2245047A1 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
ES2847288T3 (es) Péptidos derivados de preS hidrófobos modificados del virus de la hepatitis B (VHB) y su uso como vehículos para el suministro específico de compuestos al hígado
ES2441118T3 (es) Péptidos modificados hidrófobos derivados de preS del virus de la hepatitis B (HBV), y su uso como inhibidores del acceso del HBV y el HDV
EP2673004B1 (en) Hydrophobic modified peptides and their use for liver specific targeting
JP4509999B2 (ja) 医薬送達及び抗原提示システムとしてのペプチドナノ粒子
ES2708662T3 (es) Péptidos hidrofóbicos modificados para el diagnóstico hepático específico
KR20000070960A (ko) 비형 간염 바이러스 감염을 치료하기 위한 약제학적 조성물
WO2017103190A1 (en) Liver targeting of cyclic pres-derived peptides of hbv
HK1150168B (en) Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors